GlassScriptPhysician profile
Jacqueline J Littzi
NPI 1619037124
$4,992.13
in general payments reported to CMS, 2019-2025
22 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $122 · 2021: $327 · 2022: $529 · 2023: $923 · 2024: $1,106 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Gift: $83.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.54 |
| Gift | $83.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $997.12 | 2019-2025 | Tryptyr, Hydrus Microstent, Rocklatan |
| Bausch & Lomb Americas INC. | $865.81 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $440.16 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $392.11 | 2021-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $285.53 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $280.35 | 2019-2021 | |
| Oyster Point Pharma, INC. | $275.37 | 2022-2024 | Tyrvaya |
| Nova Eye, INC. | $273.12 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $243.30 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $208.99 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $155.57 | 2021-2025 | Acuvue |
| Shire North American Group INC | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.13 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $76.98 | 2019 | |
| Abbvie INC. | $50.82 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $46.67 | 2025 | |
| Ocular Therapeutix, INC. | $39.87 | 2024 | Dextenza |
| Glaukos Corporation | $33.33 | 2024 | Idose |
| Rayner Intraocular Lenses Limited | $25.77 | 2024 | Omidria |
| Kala Pharmaceuticals, INC. | $22.08 | 2021 | |
| Amgen INC. | $16.19 | 2025 | Tepezza |
| Sight Sciences, INC. | $14.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Littzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.